PT1644021E - Métodos e composições para o tratamento de distúrbios gastrointestinais - Google Patents

Métodos e composições para o tratamento de distúrbios gastrointestinais

Info

Publication number
PT1644021E
PT1644021E PT47765136T PT04776513T PT1644021E PT 1644021 E PT1644021 E PT 1644021E PT 47765136 T PT47765136 T PT 47765136T PT 04776513 T PT04776513 T PT 04776513T PT 1644021 E PT1644021 E PT 1644021E
Authority
PT
Portugal
Prior art keywords
compositions
treatment
methods
gastrointestinal disorders
gastrointestinal
Prior art date
Application number
PT47765136T
Other languages
English (en)
Inventor
Shalina Mahajan-Miklos
Jing Sun Li
Mark Currie
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34198929&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1644021(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of PT1644021E publication Critical patent/PT1644021E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT47765136T 2003-06-13 2004-06-14 Métodos e composições para o tratamento de distúrbios gastrointestinais PT1644021E (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47849203P 2003-06-13 2003-06-13
US53236103P 2003-12-23 2003-12-23
US57138604P 2004-05-14 2004-05-14

Publications (1)

Publication Number Publication Date
PT1644021E true PT1644021E (pt) 2013-01-30

Family

ID=34198929

Family Applications (1)

Application Number Title Priority Date Filing Date
PT47765136T PT1644021E (pt) 2003-06-13 2004-06-14 Métodos e composições para o tratamento de distúrbios gastrointestinais

Country Status (9)

Country Link
US (7) US20070010450A1 (pt)
EP (3) EP3342420A1 (pt)
JP (1) JP2007501866A (pt)
CA (1) CA2529307C (pt)
DK (1) DK1644021T3 (pt)
ES (1) ES2391974T3 (pt)
PL (1) PL1644021T3 (pt)
PT (1) PT1644021E (pt)
WO (1) WO2005016244A2 (pt)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
ES2330312T5 (es) * 2001-03-29 2014-01-31 Synergy Pharmaceuticals, Inc. Agonistas de receptor de guanilato ciclasa para el tratamiento de la inflamación de tejidos y de la carcionogénesis
EP2368554B1 (en) 2003-04-08 2014-12-24 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
EP3342420A1 (en) 2003-06-13 2018-07-04 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US9662390B2 (en) * 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
CA2652677A1 (en) * 2006-02-24 2007-09-07 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
MX2009010515A (es) * 2007-03-29 2009-10-19 Wyeth Corp Antagonistas del receptor opioide periferico y usos de los mismos.
EP3263571B2 (en) * 2007-03-29 2023-08-23 Progenics Pharmaceuticals, Inc. Crystal form of (r)-n-methylnaltrexone bromide and uses thereof
PE20130480A1 (es) * 2007-03-29 2013-05-08 Progenics Pharm Inc Compuestos heterociclicos como antagonistas del receptor opioide periferico
EP2636407A3 (en) * 2007-03-30 2013-11-06 Tioga Pharmaceuticals, Inc. Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome
WO2008137318A1 (en) * 2007-05-04 2008-11-13 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating disorders associated with salt or fluid retention
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20100120694A1 (en) * 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
JP5905198B2 (ja) * 2007-10-01 2016-04-20 ザ ユニヴァーシティー オヴ シカゴ 薬剤誘発性吐き気のオピオイド拮抗薬による治療
CA2713568C (en) * 2008-02-06 2016-09-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
WO2009149278A1 (en) * 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CN102186490B (zh) 2008-08-15 2015-07-29 硬木药品公司 适合口服给药的鸟苷酸环化酶-c受体激动剂多肽的稳定的固体制剂
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
MX2011005245A (es) 2008-11-19 2011-06-17 Forest Lab Holdings Ltd Forma cristalina de linaclotida.
CA2745694C (en) * 2008-12-03 2018-03-27 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
CA2770077A1 (en) 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
RU2012109415A (ru) 2009-08-13 2013-09-20 Айронвуд Фармасьютикалз, Инк. Способ модуляции фармакодинамического эффекта перорально вводимых агонистов рецептора гуанилатциклазы
RU2554087C2 (ru) 2009-12-18 2015-06-27 Айденикс Фармасьютикалз, Инк. 5,5-конденсированные ариленовые или гетероариленовые ингибиторы вируса гепатита с
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
TR201711271T4 (tr) 2010-02-17 2019-02-21 Ironwood Pharmaceuticals Inc Gastrointestinal Bozukluklar İçin Tedaviler
PL2603232T3 (pl) 2010-08-11 2020-05-18 Ironwood Pharmaceuticals, Inc. Stabilne formulacje linaklotydu
AU2011302006A1 (en) * 2010-09-15 2013-03-07 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase C agonists and methods of use
US9616097B2 (en) * 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012155114A1 (en) 2011-05-11 2012-11-15 Ironwood Pharmaceuticals, Inc. Peptides derived from uroguanylin and their use in gastrointestinal disorders
US20150086481A1 (en) * 2011-07-28 2015-03-26 Memorial Sloan-Kettering Cancer Center Diagnosis and treatment of parkinson's disease
CN104053449B (zh) 2011-08-17 2016-12-07 硬木药品公司 胃肠疾患的治疗
CA2902348C (en) 2013-02-25 2021-11-30 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2015021358A2 (en) 2013-08-09 2015-02-12 Dominique Charmot Compounds and methods for inhibiting phosphate transport
EA201690732A1 (ru) * 2013-10-10 2016-12-30 Синерджи Фармасьютикалз, Инк. Агонисты гуанилатциклазы, используемые для лечения индуцированных опиоидами дисфункций
US10259882B2 (en) 2015-05-07 2019-04-16 Agenus Inc. Anti-OX40 antibodies
US11447557B2 (en) 2015-12-02 2022-09-20 Agenus Inc. Antibodies and methods of use thereof
CA3041340A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
WO2018160067A1 (en) 2017-03-02 2018-09-07 Universiteit Van Amsterdam Specific increase of dopamine synthesis through targeting of the guanylate cyclase 2c receptor in the treatment of parkinson's disease
CN112996492A (zh) 2018-09-05 2021-06-18 阿姆斯特丹大学 Pde11或pde2抑制剂用于治疗帕金森氏疾病的用途
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport
US20240010678A1 (en) * 2020-09-08 2024-01-11 The Johns Hopkins University Method of treatment of irritable bowel syndrome

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
US5140102A (en) * 1991-09-23 1992-08-18 Monsanto Company Pentadecapeptide, guanylin, which stimulates intestinal guanylate cyclase
GB9126260D0 (en) * 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5969097A (en) * 1992-06-23 1999-10-19 G. D. Searle & Co. Human guanylin
US5734053A (en) * 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9218322D0 (en) * 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
US5395490A (en) * 1993-05-14 1995-03-07 Intertec, Ltd. Method for treating materials by the application of electromagnetic energy at resonant absorption frequencies
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
TW334423B (en) * 1993-10-22 1998-06-21 Hoffmann La Roche Tricyclic 1-aminoethylpyrrole-derivatives
CA2174928C (en) * 1993-10-26 2011-08-16 Scott A. Waldman Compositions that specifically bind to colorectal cancer cells and methods of using the same
US5879656A (en) * 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
US5962220A (en) * 1993-10-26 1999-10-05 Thomas Jefferson University Compositions that specifically bind to colorectal cells and methods of using the same
US5489670A (en) * 1993-10-29 1996-02-06 G. D. Searle & Co. Human uroguanylin
GB9514465D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US5591776A (en) * 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
GB9423910D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
DE19543628A1 (de) 1995-11-24 1997-05-28 Forssmann Wolf Georg Humanes, im Blut zirkulierendes Peptid mit insulinotroper Wirkung (GCAP-II-(89-112), (Guanylyl Cyclase C Aktivierendes Peptid II) und seine GCAP-Analoga, insbesondere das GCAP-I-(99-115), seine Anwendung als pharmakologischer Wirkstoff und Benutzung seines Wirkungsprinzipes zur Bereitstellung neuer GC-C-abhängiger insulinotroper Wirkstoffe
SK154498A3 (en) * 1996-05-10 2000-01-18 Icos Corp Carboline derivatives, process for the preparation thereof, pharmaceutical compositions containing same and use of mentioned derivatives as drugs
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
WO1999014239A1 (de) 1997-09-12 1999-03-25 Wolf Georg Forssmann Zusammensetzung zur therapie von diabetes mellitus und fettsucht
US6534221B2 (en) * 1998-03-28 2003-03-18 Gray Scale Technologies, Inc. Method for fabricating continuous space variant attenuating lithography mask for fabrication of devices with three-dimensional structures and microelectronics
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
US6326379B1 (en) * 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
US6391869B1 (en) * 1998-12-14 2002-05-21 Cellergy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
JP2002540102A (ja) * 1999-03-22 2002-11-26 ブリストル−マイヤーズ スクイブ カンパニー ｃＧＭＰホスホジエステラーゼの縮合ピリドピリダジン阻害剤
IT1312104B1 (it) * 1999-05-13 2002-04-04 Ausimont Spa Processo per ottenere pentafluoroetano per dismutazione ditetrafluorocloretano
US20030055070A1 (en) * 1999-07-01 2003-03-20 Wilma Harrison Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of selective serotonin reuptake inhibitor (SSR) induced sexual dysfunction
ES2166270B1 (es) * 1999-07-27 2003-04-01 Almirall Prodesfarma Sa Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
US6696057B1 (en) * 1999-09-22 2004-02-24 Lacpro Industries, Inc. Composition and method for treatment of gastrointestinal disorders and hyperlipidemia
EP1220872A1 (en) 1999-10-06 2002-07-10 Pharmacia Corporation Uroguanylin as an intestinal cancer inhibiting agent
US20030176421A1 (en) * 1999-12-30 2003-09-18 Watson John W. Prokinetic agents for treating gastric hypomotility and related disorders
AU2000254308A1 (en) 2000-05-17 2001-11-26 Sk Chemicals Co., Ltd. Pyrazolopyrimidinone derivatives, process for their preparation and their use
ES2222389T3 (es) * 2000-06-07 2005-02-01 Almirall Prodesfarma, S.A. Derivados de 6-fenilpirrolopirimidindiona.
JP2004501124A (ja) * 2000-06-07 2004-01-15 リリー　アイコス　リミテッド　ライアビリティ　カンパニー 化合物
US6586403B1 (en) * 2000-07-20 2003-07-01 Salpep Biotechnology, Inc. Treating allergic reactions and inflammatory responses with tri-and dipeptides
US6576644B2 (en) * 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
DE60110124T2 (de) 2000-11-08 2005-12-01 Lilly Icos Llc, Wilmington Kondensierte pyrazindionderivate als pde inhibitoren
JP2004521123A (ja) 2001-02-02 2004-07-15 ファルマシア・コーポレーション 腸癌阻害のためのウログアニリンおよびシクロオキシゲナーゼ−２阻害薬の組合わせ
US6642244B2 (en) * 2001-03-16 2003-11-04 Bristol-Myers Squibb Co. Pyrazolopyridopyrimidine inhibitors of cGMP phosphodiesterase
ES2330312T5 (es) * 2001-03-29 2014-01-31 Synergy Pharmaceuticals, Inc. Agonistas de receptor de guanilato ciclasa para el tratamiento de la inflamación de tejidos y de la carcionogénesis
EP1451211A2 (en) 2001-03-30 2004-09-01 University of Copenhagen Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere's disease
US20030096748A1 (en) * 2001-06-04 2003-05-22 The Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
EP1392729A2 (de) 2001-06-05 2004-03-03 Yalcin Cetin Verwendung eines peptids, welches guanylat cyclase c aktiviert, für die behandlung von atemwegserkrankungen über die luftwege, arzneimittel, inhalationsvorrichtung und diagnoseverfahren
US20040121961A1 (en) * 2002-02-04 2004-06-24 Jaime Masferrer Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
US20030232013A1 (en) 2002-02-22 2003-12-18 Gary Sieckman Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
MXPA05008097A (es) 2003-01-28 2006-02-08 Microbia Inc Metodos y composiciones para el tratamiento de desordenes gastrointestinales.
EP1599165A4 (en) * 2003-02-10 2010-09-08 Univ Jefferson THE USE OF GCC LIGANDS
US7494979B2 (en) * 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
EP3342420A1 (en) 2003-06-13 2018-07-04 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
BRPI0506676A (pt) * 2004-02-10 2007-05-15 Janssen Phamaceutica N V piridazinona uréias como antagonistas de integrinas alfa4
WO2005077915A1 (en) * 2004-02-10 2005-08-25 Janssen Pharmaceutica, N.V. Pyridazinones as antagonists of a4 integrins
EP1758605A4 (en) 2004-05-14 2009-07-22 Univ North Carolina PROUROGUANYLIN AS THERAPEUTIC AND DIAGNOSTIC AGENTS
GB0511066D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
WO2005016244A3 (en) 2005-10-20
US20130338063A9 (en) 2013-12-19
US20100234301A1 (en) 2010-09-16
US20120196797A1 (en) 2012-08-02
CA2529307A1 (en) 2005-02-24
EP1644021A2 (en) 2006-04-12
EP1644021A4 (en) 2011-01-19
WO2005016244A2 (en) 2005-02-24
ES2391974T3 (es) 2012-12-03
DK1644021T3 (da) 2012-10-29
PL1644021T3 (pl) 2013-01-31
US9840536B2 (en) 2017-12-12
EP2526958A1 (en) 2012-11-28
US8101579B2 (en) 2012-01-24
CA2529307C (en) 2013-12-24
JP2007501866A (ja) 2007-02-01
US20140329765A1 (en) 2014-11-06
US20160168201A1 (en) 2016-06-16
EP2526958B1 (en) 2017-10-18
US20070010450A1 (en) 2007-01-11
EP3342420A1 (en) 2018-07-04
EP1644021B1 (en) 2012-08-22
US20140296163A1 (en) 2014-10-02
US20120108525A1 (en) 2012-05-03

Similar Documents

Publication Publication Date Title
PL1644021T3 (pl) Sposoby i kompozycje do leczenia zaburzeń żołądkowo-jelitowych
IL177772A0 (en) Methods and compositions for the treatment of gastrointestinal disorders
ZA200607433B (en) Methods and compositions for the treatment of gastroin-testinal disorders
EP1853295A4 (en) METHOD AND COMPOSITIONS FOR TREATING GASTROINTESTINAL DISEASES
EP1940441A4 (en) COMPOSITIONS AND METHODS FOR TREATING GASTROINTESTINAL DISORDERS
IL175529A0 (en) Methods and compositions for the treatment of metabolic disorders
ZA200704964B (en) Methods and compositions using immunomodulatory compounds for the treatment of immunodeficiency disorders
EP1893216A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
HK1152474A1 (en) Methods and compositions for the prevention and treatment of sepsis
IL175055A0 (en) Combinations useful for the treatment of neuronal disorders
AU2003274342A8 (en) Compositions for the treatment of autoimmune disorders
EP1711197A4 (en) METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES OR DISORDERS
IL191537A0 (en) Methods and compositions for the treatment of gastrointestinal disorders
EP1699431A4 (en) COMPOSITIONS FOR THE TREATMENT OF EARLIER DISEASES AND APPLICATION PROCEDURES
AU2003286741A8 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
IL175610A0 (en) Methods and reagents for the treatment of inflammatory disorders
EP1680145A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
EP1720563A4 (en) METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION
EP1720893A4 (en) COMPOSITIONS AND METHODS FOR SYSTEMIC TREATMENT OF ARTHRITIS
IL187405A0 (en) Methods and compositions for the treatment of pain
EP1478438A4 (en) TECHNIQUES AND COMPOSITIONS FOR THE TREATMENT OF ASTHMA AND RELATED DISORDERS
ZA200510282B (en) Compositions and methods for the diagnosis and treatment of tumor
EP1740221A4 (en) METHOD AND COMPOSITIONS FOR TREATING POLYCYSTIC DISEASES
AU2003237792A8 (en) Compositions and methods for the diagnosis and treatment of tumor
GB0324523D0 (en) Compositions and methods of treatment